Clinical trials: Sweat Gland Diseases
Acne Inversa
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks.
- Trial name
- NCT04092452
- Testing
- PF-06650833, PF-06700841, PF-06826647
- Where
- 77 sites in United States, Australia and 1 more
- Volunteers
- 194 people
- Sponsor
- Pfizer
Hidradenitis Suppurativa
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and…
- Trial name
- NCT07547813
- Testing
- LAD328
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
Hidradenitis Suppurativa
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).
- Trial name
- NCT05093855
- Testing
- BDB-001 Injection
- Where
- 15 sites in China
- Volunteers
- 41 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa, Periodontal Diseases
Hidradenitis Suppurativa and Periodontal Diseases
Hidradenitis suppurativa or Verneuil's disease (HS) is a neglected and often overlooked chronic inflammatory skin disease. Nevertheless, it is frequent (1% of the general population) and deeply affects quality of life in patients…
- Trial name
- HSPDA (NCT03553888)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Hidradenitis Suppurativa
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.
- Trial name
- NCT05040698
- Testing
- Fostamatinib
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Holdsworth House Medical Practice
Hidradenitis Suppurativa
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
This is a phase 2a, open label study. As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious…
- Trial name
- NCT07077902
- Testing
- Topical roflumilast 0.3% foam
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Tulane University
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
One Lung Ventilation OLV, Esophageal Atresia
The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.
The children who will undergo OLV (one lung ventilation) through general anesthesia will be divided into two groups: The first will be intravenous infusion of dexmedetomidine at 0.4 mcg / kg / hour, and the second will be…
- Conditions
- One Lung Ventilation OLV, Esophageal Atresia, Hydrocystoma, Pneumonectomy
- Trial name
- RCT (NCT04932746)
- Testing
- Dexmedetomidine
- Where
- Syria
- Volunteers
- 110 people
- Sponsor
- Damascus University
Hidradenitis Suppurativa
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis…
- Trial name
- CLAROS (NCT07225569)
- Testing
- SAR445399
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 144 people
- Sponsor
- Sanofi
Atopic Dermatitis, Hidradenitis Suppurativa (HS)
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
- Trial name
- NCT06946641
- Testing
- QLS12010
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Hidradenitis Suppurativa
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- NCT05216224
- Testing
- ATI-450
- Where
- 20 sites in United States
- Volunteers
- 95 people
- Sponsor
- Aclaris Therapeutics, Inc.
Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\)
Botulinum Toxin-A for Hidradenitis Suppurativa
The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)
- Conditions
- Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
- Trial name
- NCT06237465
- Testing
- Normal saline, Botulinum toxin type A
- Where
- United States
- Sponsor
- Yale University
Hyperhidrosis, Residual Limbs
Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users
The aim of the present pilot study is to evaluate the effect of antiperspirant to treat residual limb hyperhidrosis with the emphasis on the utility of the iodine-starch test to identify the location of the sweating.
- Trial name
- NCT05501444
- Testing
- Topical antiperspirant
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Sophies Minde Ortopedi
Hidradenitis Suppurativa
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06956235
- Testing
- Tulisokibart
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 149 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa
Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa
This study is an open-label, dose-escalation study enrolling 15 participants. There are 3 cohorts: 1. Cohort I: 5 subjects each receiving 1 injection of IGN-AMP001 (12.5mg AMP-001 in 3ml Saline) 2.
- Trial name
- NCT04541550
- Testing
- AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose
- Where
- United States
- Sponsor
- IntegoGen, LLC
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Healthy Volunteer, Hidradenitis Suppurativa
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
LT-002-158 is an oral IRAK4 protein degrader being developed for the treatment of autoimmune disease and inflammation including Hidradenitis Suppurativa and Atopic Dermatitis.
- Conditions
- Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis
- Trial name
- NCT06082323
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)